Accepted Manuscript

Study of the Stereoselectivity of the Nucleophilic Epoxidation of 3-Hydroxy-2-methylene Esters

Antonio Latorre, José A. Sáez, Santiago Rodríguez, Florenci V. González

PII: S0040-4020(13)01702-X

DOI: 10.1016/j.tet.2013.11.014

Reference: TET 24991

To appear in: *Tetrahedron*

Received Date: 29 August 2013

Revised Date: 28 October 2013

Accepted Date: 7 November 2013

Please cite this article as: Latorre A, Sáez JA, Rodríguez S, González FV, Study of the Stereoselectivity of the Nucleophilic Epoxidation of 3-Hydroxy-2-methylene Esters, *Tetrahedron* (2013), doi: 10.1016/j.tet.2013.11.014.

Study of the Stereoselectivity of the Nucleophilic Epoxidation of 3-Hydroxy-2-methylene Esters

Antonio Latorre, Jos˘ A. S‡ez, Santiago Rodr'guez, and Florenci V. Gonz‡lez*



Study of the Stereoselectivity of the Nucleophilic Epoxidation of 3-Hydroxy-2-methylene Esters

Antonio Latorre, José A. Sáez, Santiago Rodríguez, Florenci V. González*

Departament de Química Inorgànica i Orgànica, Universitat Jaume I, 12080 Castelló, Spain

Abstract

The diastereoselectivity of the nucleophilic epoxidation of 3-hydroxy-2-methylene esters has been studied. The 3-hydroxy-2-methylene esters were obtained through a Morita-Baylis-Hillman reaction. The resulting epoxyesters were treated with thiophenol for transformation into 2,3-dihydroxy-2-((phenylthio)methyl) which upon treatment with triphosgene afforded the corresponding cyclic carbonates.

Introduction

Stereoselective synthesis of α,β-epoxyesters is of considerable synthetic interest because a number of compounds can be obtained by the opening of the oxirane ring.[1-9] A convenient method for the preparation of α,β-epoxyesters is via nucleophilic epoxidation of chiral α,β-unsaturated esters.[2] We previously reported that the nucleophilic epoxidation of γ-hydroxy-α,β-unsaturated esters[8] (Scheme 1) is a diastereoselective reaction that favor

* Corresponding author: Tel. 34 964729156. Fax: 34 964728214. E-mail: fgonzale@uji.es

the *syn* isomer. We have also reported that the stereoselectivity depends highly on the substitution of the double bond and that high *syn* stereoselectivity (dr >19:1) is observed for the α-methyl-substituted enoates[9] (Scheme 1). Free hydroxyl group resulted to be key for the control of the stereoselectivity. The nucleophilic epoxidation of methyl 2-methylene-3-*tert*-butyldimethylsilyloxycarboxylate esters has been recently reported by A. Myers to get the *anti* diastereomer with high selectivity[12] (Scheme 1). The epoxidation of Morita-Baylis-Hillman adducts is an interesting transformation because the resulting epoxides can be used in the total synthesis of interesting natural products.[10-12] We now report a study of the stereoselectivity of the nucleophilic epoxidation of β-hydroxy-α-methylene esters.



Scheme 1. Stereoselective nucleophilic epoxidations of unsaturated esters.

Results and discussion

We wanted to study the selectivity of epoxidation of 3-hydroxy-methylene carboxylate esters with a range of R alkyl and aryl groups (Scheme 2). For the preparation of the substrates, a comparison of different experimental procedures was performed as shown in Table 1. Most of the substrates were prepared in good yield using DABCO as a base and a (1:1) mixture of dioxane:water as reported.[13] We obtained higher yields when the reaction was performed at higher concentrations (10 M) than reported (see experimental section). Compounds **1i** and **1j** were

obtained in best yields under solvent-free conditions and longer period of time, and compounds **1m** and **1n** were prepared using dimethylsulfoxide as a solvent.



1a, R = Me
1b, R = Et
1c, R = *n*-Pr
1d, R = *i*-Bu
1e, R = Chx
1f, R = CH_2CH_2Ph
1g, R = CH=CHPh
1h, R = Ph
1i, R = *p*-Tol
1j, R = *p*-MeOPh
1k, R = *p*-FPh
1l, R = *p*-ClPh
1m, R = *m*-ClPh
1n, R = *o*-ClPh
1o, R = *p*-BrPh
1p, R = *o*-NO_2Ph
1q, R = *m*-NO_2Ph
1r, R = *p*-NO_2Ph
1s, R = Furfuryl

Scheme 2. Preparation of substrates.



TABLE 1. Preparation of esters **1**.

Entry	Substrate	Conditions	Yield
1	**1a**	DABCO, dioxane:H_2O (1:1), 10M, 48h, rt	99
2	**1b**	DABCO, dioxane:H_2O (1:1), 10M, 48h, rt	70
3	**1c**	DABCO, dioxane:H_2O (1:1), 10M, 48h, rt	99
4	**1d**	DABCO, dioxane:H_2O (1:1), 10M, 48h, rt	85
5	**1e**	DABCO, dioxane:H_2O (1:1), 10M, 48h, rt	81
6	**1f**	DABCO, dioxane:H_2O (1:1), 10M, 48h, rt	99
7	**1g**	DABCO, dioxane:H_2O (1:1), 10M, 48h, rt	99
8	**1h**	DABCO, dioxane:H_2O (1:1), 12M, 48h, rt	99

9	**1i**	DABCO, solvent-free 4 days, rt	82
10	**1j**	DABCO, solvent-free 5 weeks, rt	77
11	**1k**	DABCO, dioxane:H_2O (1:1), 10M, 36h, rt	99
12	**1l**	DABCO, solvent-free 5 days, rt	94
13	**1m**	DABCO, DMSO 7M, 4 days, rt	99
14	**1n**	DABCO, DMSO 7M, 4 days, rt	99
15	**1o**	DABCO, dioxane:H_2O (1:1), 10M, 36h, rt	89
16	**1p**	DABCO, dioxane:H_2O (1:1), 10M, 16h, rt	95
17	**1q**	DABCO, dioxane:H_2O (1:1), 10M, 16h, rt	87
18	**1r**	DABCO, dioxane:H_2O (1:1), 10M, 3h, rt	83
19	**1s**	DABCO, dioxane:H_2O (1:1), 10M, 20h, rt	85

Esters **1** were epoxidized using lithium *tert*-butylperoxide (2 equivalents) as the oxidizing reagent in THF as solvent at -20 ºC.[2,8,9] Table 2 shows that the **2** *syn* isomer was the major product in all cases. For the aliphatic series (compounds **1a-f**), the higher steric volume of the R pendant alkyl group the higher stereoselectivity is observed (entries 1-6). When the R is an alkenyl group then the epoxidation reaction is not stereoselective (entry 7). Compounds **1h-s** having an aromatic group gave the corresponding *syn* isomer **2** in very good selectivity.



TABLE 2. Epoxidation of compounds **1**.

Entry	Substrate	**2/3**	Yield[a]

1	Me	67/33	72
2	Et	76/24	70
3	n-Pr	81/19	79
4	i-Bu	81/19	71
5	Chx	92/8	85
6	$PhCH_2CH_2$	77/23	59
7	PhCH=CH	53/47	47
8	Ph	93/7	68
9	p-Tol	89/11	82
10	p-MeOPh	92/8	73
11	p-FPh	90/10	65
12	p-ClPh	84/16	52
13	m-ClPh	92/8	38
14	o-ClPh	92/8	52
15	p-BrPh	90/10	68
16	o-NO2Ph	83/17	43
17	m-NO2Ph	80/20	60
18	p-NO2Ph	91/9	65
19	Furfuryl	93/7	69

[a] Isolated yield of products corresponds to mixtures of *syn* and *anti* diastereomers.

We also epoxidized compound **1h** by using oxidants other than lithium *tert*-butylperoxide (Table 3). If the reaction was carried out using *tert*-butyl hydrogenperoxide in the presence of substoichiometric amount of base (entry 1), then a slightly lower selectivity was observed compared to the reaction carried out using a stoichiometric amount of oxidant (entry 8, Table 2). Lithium cumylperoxide gave similar result to lithium *tert*-butylperoxide (entry 2). On the other hand, in the alkaline peroxides series, potassium gave poorer stereoselectivity than either lithium or sodium (entries 1 and 6–8). The yield of the epoxidation using *m*-CPBA (entry 3) was low at room temperature but it

increased at higher temperature (entry 4), affording the *syn* isomer as the major one. When *m*-CPBA was used in the presence of potassium carbonate[14] (entry 5), only starting material was recovered.



TABLE 3. Epoxidation of compound **1h**.

Entry	Conditions[a]	**2h/3h**	Yield (%)[b]
1	TBPLi	88/12	66
2	CMPLi	91/9	72
3	mCPBA	90/10	28
4	mCPBA	88/12	80
5	mCPBA	-	NR
6	TBPNa	85/15	41
7	TBPNa	87/13	62
8	TBPK	83/17	61

[a] For entry 1: 1.5 equiv of TBHP, 0.8 equiv of MeLi, THF, -20 ºC, 20 h. For entry 2: 1.5 equiv of CMHP, 1.1 equiv of MeLi, THF, -20 ºC, 20 h. For entry 3: 2.1 equiv of mCPBA, DCM, rt, 96 h. For entry 4: 2.1 equiv of mCPBA, 70 ºC (sealed tube), 96 h. For entry 5: 2.5 equiv of mCPBA, 1.3 equiv of K_2CO_3, DCM, rt, 96 h. For entry 6: 2.0 equiv of TBHP, 1.0 equiv of *t*-BuONa, THF, 0 ºC, 3 h. For entry 7: 2.0 equiv of TBHP, 0.25 equiv of *t*-BuONa, THF, 0 ºC, 3 h. For entry 8: 2.0 equiv of TBHP, 0.25 equiv of *t*-BuOK, THF, 0 ºC, 3 h. [b] Isolated yield of products corresponds to mixtures of *syn* and *anti* diastereomers.

The stereochemistry of epoxides **2b** and **2h** was confirmed by comparison with already reported data.[12,15] The epoxyesters **2d, 3d**, **2e** and **3e** were transformed into cyclic carbonates through a one-pot sequence: treatment with thiophenol in the presence of a base which resulted in the opening of the oxirane ring and then addition of triphosgene to give carbonates **4, 5, 6** and **7**, respectively (Scheme 3). The stereochemical assignment of the carbonates was performed by NOE experiments (Scheme 3). Carbonates **4** and **6** gave NOE between H-5 and methyl ester whilst **5** and **7** gave NOE between H-5 and methylene from the (phenylthio)methyl group.



Scheme 3. Cyclic carbonates **4-7**.

Conclusions

In summary, the diastereoselectivity of the nucleophilic epoxidation of 3-hydroxy-2-methylene esters has been studied. The *syn* isomer was the major one in all cases. The resulting 3-hydroxy 2-epoxyesters were treated with thiophenol for transformation into 2,3-dihydroxy-2-((phenylthio)methyl) which upon treatment with triphosgene afforded the corresponding cyclic carbonates.

Experimental Section

General Experimental Methods. All solvents used in reactions were freshly distilled from appropriate drying agents before use. ^{1}H NMR spectra and ^{13}C NMR spectra were measured in $CDCl_3$ (^{1}H, 7.24 ppm; ^{13}C 77.0 ppm) solution at 30 °C on a 300 MHz or a 500 MHz NMR spectrometer. IR spectra were recorded as oil films or KBr discs or NaCl pellets on a FT-IR spectrometer. EM Science Silica Gel 60 was used for column chromatography while TLC was

performed with precoated plates (Kieselgel 60, F_{254}, 0.25 mm). Unless otherwise specified, all reactions were carried out under argon atmosphere with magnetic stirring.

General experimental procedure for the preparation of compounds 1a-s:

To a solution of aldehyde (1 mmol) in dioxane-water (1:1) (0.1 mL) was added methyl acrylate (3 mmol) and DABCO (1 mmol). The reaction was monitored by TLC. Upon completion, water (70 mL) was added and poured onto a separatory funnel and extracted with ethyl ether or dichloromethane (3 x 30 mL), dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The crude was purified through chromatography (silica-gel, hexanes/ethyl acetate (8:2), (6:4)) to afford the desired compound.

Methyl 3-hydroxy-2-methylenebutanoate 1a.[16] ^{1}H NMR (500 MHz, $CDCl_3$) δ 6.19 (1H, s), 5.81 (1H, s), 4.59 (1H, q, J = 6.5 Hz), 3.76 (3H, s), 2.61 (1H, br s), 1.36 (3H, d, J = 6.5 Hz).^{13}C NMR (125 MHz, $CDCl_3$) δ 167.1, 143.6, 124.0, 67.2, 51.8, 22.1 ppm.

Methyl 3-hydroxy-2-methylenepentanoate 1b.[17] ^{1}H NMR (500 MHz, $CDCl_3$) δ 6.22 (1H, s), 5.78 (s, 1H), 4.31 (1H, t, J = 7.0Hz), 3.76 (3H, s), 2.43 (1H, br s), 1.73-1.61 (2H, m), 0.93 (3H, t, J = 7.4Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 167.0, 142.3, 124.7, 72.0, 51.5, 29.0, 10.0 ppm.

Methyl 3-hydroxy-2-methylenehexanoate 1c.[18] ^{1}H NMR (500 MHz, $CDCl_3$) δ 6.20 (1H, s), 5.78 (1H, s), 4.38 (1H, t, J = 6.5 Hz), 3.76 (3H, s), 2.41 (1H, br s), 1.63-1.58 (2H, m), 1.49-1.45 (1H, m), 1.31-1.38 (1H, m), 0.90 (3H, t, J = 6.7 Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 167.0, 142.5, 124.7, 71.3, 52.0, 38.5, 19.0, 14.0 ppm.

Methyl 3-hydroxy-5-methyl-2-methylenehexanoate 1d.[18] ^{1}H NMR (500 MHz, $CDCl_3$) δ 6.18 (1H, s), 5.78 (1H, s), 4.45 (1H, dd, J = 8.5, 4.3Hz), 3.76 (3H, s), 2.40 (1H, br s), 1.80-1.75 (1H, m), 1.58-1.51 (1H, m), 1.44-1.38 (1H, m), 0.92 (6H, m). ^{13}C NMR (125 MHz, $CDCl_3$) δ 167.0, 142.8, 124.6, 71.3, 69.9, 51.9, 45.5, 24.8, 23.3, 21.8 ppm.

Methyl 2-(cyclohexyl(hydroxy)methyl)acrylate 1e.[19] ^{1}H NMR (500 MHz, $CDCl_3$) δ 6.23 (1H, s), 5.71 (1H, s), 4.06 (1H, d, J = 7.2 Hz), 3.76 (3H, s), 2.44 (1H, br s), 1.94 (1H, m), 1.50-1.76 (5H, m), 1.24-0.92 (5H, m). ^{13}C NMR (125 MHz, $CDCl_3$) δ 167.0, 141.2, 126.0, 53.4, 52.0, 42.4, 29.8, 28.1, 26.3, 26.1, 25.9 ppm.

Methyl 3-hydroxy-2-methylene-5-phenylpentanoate 1f.[20] ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.30-7.17 (5H, m), 6.24 (1H, s), 5.81 (1H, s), 4.42 (1H, dd, J = 7.5, 5.7Hz), 3.77 (3H, s), 2.85-2.79 (1H, m), 2.73-2.69 (1H, m), 2.42 (1H, br s), 2.00-1.95 (1H, m). ^{13}C NMR (125 MHz, $CDCl_3$) δ 167.0, 141.8, 128.5, 125.9, 125.0, 70.1, 51.8, 38.0, 32.0 ppm.

(*E*)-methyl 3-hydroxy-2-methylene-5-phenylpent-4-enoate 1g.[19] ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.39-7.22 (5H, m), 6.67 (1H, d, J = 16.0Hz), 6.29 (2H, m), 5.91 (1H, s), 5.13 (1H, m), 3.78 (3H, s), 2.97 (1H, br s). ^{13}C NMR (125 MHz, $CDCl_3$) δ 166.7, 141.3, 136.5, 131.5, 129.2, 128.5, 127.8, 126.6, 125.8, 72.1, 52.0 ppm.

Methyl 2-(hydroxy(phenyl)methyl)acrylate 1h.[18] ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.38-7.26 (5H, m), 6.33 (1H, s), 5.83 (1H, s), 5.56 (1H, s), 3.72 (3H, s). ^{13}C NMR (125 MHz, $CDCl_3$) δ 166.7, 142.3, 141.6, 128.3, 127.7, 126.8, 125.6, 72.7, 51.8 ppm.

Methyl 2-(hydroxy(*p*-tolyl)methyl)acrylate 1i.[18] ^{1}H NMR (300 MHz, $CDCl_3$) δ 7.26 (2H, d, J = 8.0Hz), 7.15 (2H, d, J = 8.0Hz), 6.32 (1H, s), 5.85 (1H, s), 5.53 (1H, s), 3.71 (3H, s), 2.34 (3H, s). ^{13}C NMR (125 MHz, $CDCl_3$) δ 166.8, 142.1, 138.4, 137.5, 129.1, 126.5, 125.8, 73.1, 51.9, 21.1 ppm.

Methyl 2-(hydroxy(4-methoxyphenyl)methyl)acrylate 1j.[20] ^{1}H NMR (300 MHz, $CDCl_3$) δ 7.28 (2H, d, J = 8.8Hz), 6.86 (2H, d, J = 8.7Hz), 6.31 (1H, s), 5.84 (1H, s), 5.52 (1H, s), 3.79 (3H, s), 3.71 (3H, s). ^{13}C NMR (75 MHz, $CDCl_3$) δ 166.8, 159.2, 142.2, 133.5, 127.9, 125.5, 113.8, 72.7, 55.2, 51.9 ppm.

Methyl 2-((4-fluorophenyl)(hydroxy)methyl)acrylate 1k.[20] ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.33 (2H, dd, J = 8.5, 5.5Hz), 7.01 (2H, t, J = 8.7Hz), 6.32 (1H, s), 5.82 (1H, s), 5.53 (1H, s), 3.73 (3H, s), 3.02 (1H, br s). ^{13}C NMR (125 MHz, $CDCl_3$) δ 166.6, 162.3 (d, J = 245Hz), 141.9, 137.0, 128.3 (dd, J = 7.2, 21.3Hz), 126.0 (dd, J = 15.0, 21.3Hz), 115.2 (dd, J = 12.5, 22.5Hz), 72.6, 52.2 ppm.

Methyl 2-((4-chlorophenyl)(hydroxy)methyl)acrylate 1l.[18] ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.54 (1H, m), 7.34 (1H, m), 7.21-7.30 (2H, m), 6.32 (1H, s), 5.97 (1H, s), 5.58 (1H, m), 3.76 (3H, s), 3.26 (1H, br s). ^{13}C NMR (125 MHz, $CDCl_3$) δ 166.6, 141.6, 139.8, 133.6, 128.6, 127.9, 126.3, 72.7, 52.0 ppm.

Methyl 2-((3-chlorophenyl)(hydroxy)methyl)acrylate 1m.[20] ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.37 (1H, s), 7.26 (3H, m), 6.34 (1H, s), 5.83 (s, 1H), 5.51 (1H, s), 3.72 (s, 3H), 3.03 (1H, br s). ^{13}C NMR (125 MHz, $CDCl_3$) δ 166.5, 143.4, 141.4, 134.4, 129.7, 127.9, 126.7, 126.6, 124.7, 72.7, 52.0 ppm.

Methyl 2-((2-chlorophenyl)(hydroxy)methyl)acrylate 1n.[20] ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.54 (1H, m), 7.34 (1H, m), 7.21-7.30 (2H, m), 6.32 (1H, s), 5.97 (1H, s), 5.58 (1H, m), 3.76 (3H, s), 3.25 (1H, br s). ^{13}C NMR (125 MHz, $CDCl_3$) δ 166.9, 140.9, 134.5, 132.8, 128.9, 128.1, 127.0, 126.8, 68.9, 52.0 ppm.

Methyl 2-((4-bromophenyl)(hydroxy)methyl)acrylate 1o.[20] ^{1}H NMR (300 MHz, $CDCl_3$) δ 7.47 (2H, m), 7.25 (2H, m), 6.33 (1H, s), 5.82 (1H, s), 5.51 (1H, m), 3.73 (3H, s), 3.04 (1H, br s). ^{13}C NMR (75 MHz, $CDCl_3$) δ 166.4, 141.9, 140.6, 131.4, 128.6, 125.9, 121.6, 71.9, 51.9 ppm.

Methyl 2-((2-nitrophenyl)(hydroxy)methyl)acrylate 1p.[18] ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.95 (1H, dd, J = 8.2, 1.3Hz), 7.75 (1H, dd, J = 7.9, 1.3Hz), 7.64 (1H, td, J = 7.7, 1.3Hz), 7.46 (1H, td, J = 8.5, 1.4Hz), 6.37 (1H, s), 6.20 (1H, s), 5.73 (1H, s), 3.73 (3H, s), 3.35 (1H, br s). ^{13}C NMR (75 MHz, $CDCl_3$) δ 163.8, 145.6, 138.5, 133.7, 130.8, 126.3, 126.0, 123.7, 121.9, 64.7, 49.5 ppm.

Methyl 2-((3-nitrophenyl)(hydroxy)methyl)acrylate 1q.[18] ^{1}H NMR (500 MHz, $CDCl_3$) δ 8.26 (1H, m), 8.14 (1H, ddd, J = 8.2, 2.3, 1.2Hz), 7.75 (1H, m), 7.52 (1H, t, J = 7.92 Hz), 6.41 (1H, s), 5.89 (1H, s), 5.63 (1H, s), 3.75 (3H, s), 3.25 (1H, br s). ^{13}C NMR (125 MHz, $CDCl_3$) δ 166.2, 148.3, 143.7, 141.0, 132.8, 129.5, 126.9, 122.8, 121.7, 72.4, 52.3 ppm.

Methyl 2-((4-nitrophenyl)(hydroxy)methyl)acrylate 1r.[18] ^{1}H NMR (500 MHz, $CDCl_3$) δ 8.18 (2H, d, J = 10.9Hz), 7.56 (2H, d, J = 10.9Hz), 6.38 (1H, s), 5.86 (1H, s), 5.62 (1H, m), 3.73 (3H, s), 3.32 (1H, br s). ^{13}C NMR (125 MHz, $CDCl_3$) δ 166.4, 148.6, 143.7, 141.0, 127.3, 127.2, 123.6, 72.7, 52.2 ppm.

Methyl 2-(furan-2-yl(hydroxy)methyl)acrylate 1s.[18] ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.35 (1H, s), 6.37 (1H, s), 6.31 (1H, m), 6.24 (1H, m), 5.93 (1H, s), 5.57 (1H, s), 3.74 (3H, s), 3.21 (1H, br s). ^{13}C NMR (125 MHz, $CDCl_3$) δ 166.4, 154.1, 142.3, 143.7, 139.5, 126.7, 110.4, 107.1, 67.2, 52.0 ppm.

General experimental procedure for the epoxidation of esters 1a-s:

To a -78 ºC cold THF (3.5 mL) was added TBHP (3.3 M in toluene) (2 mmol) and then methyllithium (1.6M in hexanes) (1.7 mmol). The resulting mixture was stirred at -78 ºC for 15 min and then a solution of compound **1** (1 mmol) in THF (2 mL) was added drop wise and then the mixture was left at -20 ºC (fridge) for 20 h. Then solid Na_2SO_3 (120 mg) was added in one portion and stirred for 15 min, then diluted with water and extracted with Et_2O (3 x 30 mL), the organic layers were washed (brine), dried (Na_2SO_4), and concentrated. The crude oil was purified through chromatography (silica-gel, hexanes/EtOAc (7:3) and (1:1)).

Methyl 2-(1-hydroxyethyl)oxirane-2-carboxylate 2a/3a. (yield= 167 mg, 99%) (Ratio of diastereomers 67/33). ^{1}H NMR (500 MHz, $CDCl_3$) δ 4.33 (1H, q, J = 6.6Hz) (minor), 4.16 (1H, q, J = 6.4Hz) (major), 3.71 (3H, s), 3.10 (1H, d, J = 5.9Hz) (major), 4.64 (1H, d, J = 6.1Hz) (minor), 2.99 (1H, d, J = 6.0Hz) (minor), 2.96 (1H, d, J = 5.8Hz) (major), 2.08 (1H, br s), 1.31 (3H, d, J = 6.4Hz) (major), 1.29 (3H, d, J= 6.6Hz) (minor). ^{13}C NMR (125 MHz, $CDCl_3$) δ 170.0 (minor), 169.9 (major), 65.1 (major), 64.9 (minor), 59.6 (minor), 59.0 (major), 52.5 (major), 52.4 (minor), 49.3 (minor), 49.2 (major), 18.6 (minor), 18.2 (major) ppm. IR (KBr) δ 3932, 3839, 2984, 2363, 1738, 1519, 1382, 1285, 1173, 1095, 971, 913, 853 cm^{-1}. HRMS *m/z* calcd. for $C_6H_{10}O_4Na$ [M+Na$^+$]: 169.0477, found: 169.0478.

Methyl 2-(1-hydroxypropyl)oxirane-2-carboxylate 2b/3b. (yield= 128 mg, 70%) (Ratio of diastereomers 76/24). ^{1}H NMR (500 MHz, $CDCl_3$) δ 3.75 (1H, m), 3.71 (3H, s), 3.12 (1H, d, J = 6.0Hz), 2.98 (1H, d, J = 6.0Hz), 2.55 (1H, br s), 1.72 (1H, m), 1.48 (1H, m), 0.98 (3H, t, J= 6.7Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 170.0, 71.0, 50.1, 52.5, 49.6, 26.0, 9.9 ppm. IR (KBr) δ 3770, 3457, 2939, 2360, 1869, 1637, 1541, 1440, 1348, 1197, 1139, 1055, 950, 758 cm^{-1}. HRMS *m/z* calcd. for $C_7H_{12}O_4Na$ [M+Na$^+$]: 183.0633, found: 183.0636.

(Yield **2c/3c** = 99%)

***syn*-Methyl 2-(1-hydroxybutyl)oxirane-2-carboxylate 2c.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 3.84-3.87 (1H, m), 3.78 (3H, s), 3.12 (1H, d, J = 5.9Hz), 2.98 (1H, d, J = 5.9Hz), 1.69-1.40 (4H, m), 0.94 (3H, t, J= 7.2Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 170.0, 69.3, 58.3, 52.4, 49.6, 35.0, 18.7, 13.8 ppm. IR (KBr) δ 3649, 2960, 2361, 1740, 1560, 1457, 1382, 1197, 1139, 1077, 983, 760 cm^{-1}. HRMS *m/z* calcd. for $C_8H_{14}O_4Na$ [M+Na$^+$]: 197.0790, found: 197.0786.

***anti*-Methyl 2-(1-hydroxybutyl)oxirane-2-carboxylate 3c.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 4.12-4.10 (1H, m), 3.78 (3H, s), 3.08 (1H, d, J = 6.0Hz), 2.98 (1H, d, J = 6.0Hz), 1.77 (1H, br s), 1.61-1.37 (4H, m), 0.94 (3H, t, J= 7.1Hz).

^{13}C NMR (125 MHz, $CDCl_3$) δ 170.0, 69.0, 59.4, 52.5, 49.3, 35.1, 18.9, 13.7 ppm. IR (KBr) δ 3466, 2960, 1739, 1639, 1567, 1441, 1356, 1287, 1212, 1197, 1138, 1129, 1036, 982, 957 cm^{-1}.

(Yield **2d/3d** = 71%)

***syn*-Methyl 2-(1-hydroxy-3-methylbutyl)oxirane-2-carboxylate 2d.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 3.92 (1H, dd, J = 3.8, 9.2Hz), 3.78 (3H, s), 3.12 (1H, d, J = 5.9Hz), 2.98 (1H, d, J = 5.9Hz), 1.93-1.86 (1H, m), 1.41-1.51 (2H, m), 0.95 (6H, t, J= 6.5Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 170.0, 68.0, 58.5, 52.5, 49.6, 41.8, 24.4, 23.5, 21.4 ppm. IR (KBr) δ 3743, 2956, 2361, 1738, 1438, 1368, 1171, 1116, 1078, 994, 919, 864, 758 cm^{-1}. HRMS *m/z* calcd. for $C_9H_{16}O_4Na$ [M+Na^+]: 211.0946, found: 211.0942.

***anti*-Methyl 2-(1-hydroxy-3-methylbutyl)oxirane-2-carboxylate 3d.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 4.20 (1H, dd, J = 3.8, 9.2Hz), 3.77 (3H, s), 3.09 (1H, d, J = 5.9Hz), 2.98 (1H, d, J = 5.9Hz), 2.06-1.96 (1H, br s), 1.76-1.82 (1H, m), 1.48-1.51 (1H, m), 1.27-1.35 (1H, m), 0.95 (6H, t, J= 6.5Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 170.0, 67.5, 59.6, 52.5, 49.3, 42.0, 24.4, 23.5, 21.3 ppm. IR (KBr) δ 3491, 2957, 2393, 1738, 1440, 1368, 1184, 1115, 1094, 993, 919, 879 cm^{-1}.

***syn*-Methyl 2-(cyclohexyl(hydroxy)methyl)oxirane-2-carboxylate 2e.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 3.78 (3H, s), 3.39 (1H, d, J = 6.7Hz), 3.11 (1H, d, J = 5.9Hz), 2.96 (1H, d, J = 5.9Hz), 2.12 (1H, br s), 1.88 (1H, m), 1.75-1.63 (5H, m), 1.26-1.03 (5H, m). ^{13}C NMR (125 MHz, $CDCl_3$) δ 170.1, 75.1, 57.3, 52.4, 49.7, 41.2, 29.3, 28.2, 26.2, 26.0, 25.8 ppm. IR (KBr) δ 3799, 2930, 2669, 2342, 1741, 1377, 1306, 1200, 1124, 1087, 1030, 932, 761 cm^{-1}. HRMS *m/z* calcd. for $C_{11}H_{18}O_4Na$ [M+Na^+]: 237.1103, found: 237.1105.

***anti*-Methyl 2-(cyclohexyl(hydroxy)methyl)oxirane-2-carboxylate 3e.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 3.77 (3H, s), 3.69 (1H, d, J = 6.5Hz), 3.02 (1H, d, J = 5.9Hz), 2.97 (1H, d, J = 5.9Hz), 1.94 (1H, m), 1.78-1.64 (5H, m), 1.30-0.94 (5H, m). ^{13}C NMR (125 MHz, $CDCl_3$) δ 169.8, 74.5, 65.7, 58.7, 52.5, 49.6, 41.5, 29.6, 28.2, 26.1, 25.8, 15.1 ppm. IR (KBr) δ 3752, 2936, 2668, 2341, 1740, 1422, 1232, 1153, 1104, 1069, 1052, 974, 957 cm^{-1}.

***syn*-Methyl 2-(1-hydroxy-3-phenylpropyl)oxirane-2-carboxylate 2f.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.33-7.20 (5H, m), 3.95 (1H, m), 3.77 (3H, s), 3.12 (1H, d, J = 6.0Hz), 2.95 (1H, d, J = 6.0Hz), 2.93-2.88 (1H, m), 2.77-2.65 (1H,

m), 2.20-2.01 (1H, m), 1.82-1.93 (1H, m). ^{13}C NMR (125 MHz, $CDCl_3$) δ 170.0, 141.5, 128.4, 126.1, 68.9, 58.3, 52.6, 49.3, 34.8, 31.7 ppm. IR (KBr) δ 3873, 3063, 3003, 2924, 2364, 1748, 1290, 1240, 1132, 1075, 754, 701 cm^{-1}.

***anti*-Methyl 2-(1-hydroxy-3-phenylpropyl)oxirane-2-carboxylate 3f.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.30-7.17 (5H, m), 4.11 (1H, d, J = 9.3Hz), 3.76 (3H, s), 3.05 (1H, d, J = 6.0Hz), 3.00 (1H, d, J = 6.0Hz), 2.93-2.87 (1H, m), 2.75-2.69 (1H, m), 1.99-1.93 (1H, m), 1.89-1.82 (1H, m), 1.54 (1H, br s). ^{13}C NMR (125 MHz, $CDCl_3$) δ 170.0, 141.3, 128.4, 126.0, 68.9, 59.1, 52.3, 49.3, 34.5, 31.8 ppm.

(*E*)-Methyl 2-(1-hydroxy-3-phenylallyl)oxirane-2-carboxylate 2g/3g. (yield= 103 mg, 47%) (Ratio of diastereomers 53/47). ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.40-7.24 (m, 5H), 6.74 (1H, d, J = 16.0Hz) (major and minor), 6.27 (1H, dd, J = 6.3, 12.0Hz) (major), 6.23 (1H, dd, J = 5.8, 13.2Hz) (minor), 4.85 (1H, dd, J = 6.3, 1.3Hz) (minor), 4.71 (1H, dd, J = 6.5, 1.2Hz) (major), 3.80 (3H, s) (major), 3.79 (3H, s) (minor), 3.15 (1H, d, J = 5.9Hz) (major), 3.13 (1H, d, J = 6.1Hz) (minor), 3.06 (1H, d, J = 6.1Hz) (minor), 3.00 (1H, d, J = 5.9Hz) (major). ^{13}C NMR (125 MHz, $CDCl_3$) δ 169.8 (minor), 169.7 (major), 136.2 (minor), 136.1 (major), 133.5 (major), 133.1 (minor), 128.6, 128.1, 128.0, 126.7 (major and minos), 125.9 (minor), 125.6 (major), 70.7 (major), 70.0 (minor), 59.0 (minor), 58.5 (major), 52.7, 52.6 (major and minor), 49.9 (major), 49.2 (minor) ppm. HRMS *m/z* calcd. for $C_{13}H_{14}O_4Na$ [$M+Na^+$]: 257.0790, found: 257.0792.

***syn*-Methyl 2-(hydroxy(phenyl)methyl)oxirane-2-carboxylate 2h.**[10] ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.43-7.30 (5H, m), 5.18 (1H, s), 3.73 (3H, s), 3.12 (1H, d, J = 5.9Hz), 2.86 (1H, d, J = 5.9Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 169.7, 138.4, 128.4, 127.0, 71.7, 59.0, 52.6, 49.7 ppm. IR (KBr) δ 3487, 3064, 2910, 2359, 1739, 1269, 1160, 1082, 1027, 947, 757 cm^{-1}. HRMS *m/z* calcd. for $C_{11}H_{12}O_4Na$ [$M+Na^+$]: 231.0633, found: 231.0632.

***syn*-Methyl 2-(hydroxy(*p*-tolyl)methyl)oxirane-2-carboxylate 2i.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.29 (2H, d, J = 8.0Hz), 7.26 (2H, d, J = 8.0Hz), 5.15 (1H, s), 3.72 (3H, s), 3.11 (1H, d, J = 5.9Hz), 2.86 (1H, d, J = 5.9Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 169.8, 137.9, 135.5, 128.9, 127.0, 71.4, 59.1, 52.6, 49.6, 21.1 ppm. IR (KBr) δ 3502, 3005, 2923, 1743, 1197, 1125, 1020, 943, 837, 765, 686 cm^{-1}. HRMS *m/z* calcd. for $C_{12}H_{14}O_4Na$ [$M+Na^+$]: 245.0790, found: 245.0787.

***syn*-Methyl 2-(hydroxy(4-methoxyphenyl)methyl)oxirane-2-carboxylate 2j.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.33 (2H, d, J = 8.8Hz), 6.87 (2H, d, J = 8.8Hz), 5.16 (1H, s), 3.79 (3H, s), 3.67 (3H, s), 3.12 (1H, d, J = 6.0Hz), 2.85 (1H, d, J = 6.0Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 169.8, 159.5, 130.4, 128.5, 113.8, 71.2, 59.1, 55.2, 52.6, 49.5 ppm. IR (KBr) δ 3493, 3003, 2910, 1742, 1197, 1124, 1031, 978, 917, 836, 756 cm^{-1}. HRMS *m/z* calcd. for $C_{12}H_{14}O_5Na$ [M+Na$^+$]: 261.0739, found: 261.0738.

***syn*-Methyl 2-((4-fluorophenyl)(hydroxy)methyl)oxirane-2-carboxylate 2k.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.40 (2H, dd, J = 8.5, 5.5Hz), 7.03 (2H, t, J = 8.7Hz), 5.15 (1H, s), 3.73 (3H, s), 3.13 (1H, d, J = 6.0Hz), 2.85 (1H, d, J = 6.0Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 169.7, 162.2 (d, J = 245Hz), 134.2, 129.0 (dd, J = 7.2, 21.3Hz), 115.2 (dd, J = 12.5, 22.5Hz), 71.1, 65.8, 52.7, 49.6 ppm. IR (KBr) δ 3477, 3070, 2958, 2342, 1737, 1509, 1398, 1271, 1197, 1128, 1045, 980, 842, 756 cm^{-1}. HRMS *m/z* calcd. for $C_{11}H_{11}FO_4Na$ [M+Na$^+$]: 249.0539, found: 249.0535.

***syn*-Methyl 2-((4-chlorophenyl)(hydroxy)methyl)oxirane-2-carboxylate 2l.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.37 (2H, d, J = 8.0Hz), 7.32 (2H, d, J = 8.0Hz), 5.29 (1H, s), 3.73 (3H, s), 3.14 (1H, d, J = 6.0Hz), 2.88 (1H, d, J = 6.0Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 169.6, 137.0, 134.1, 128.6, 128.5, 71.2, 58.7, 52.7, 49.7 ppm. IR (KBr) δ 3518, 3001, 2929, 1723, 1411, 1287, 1160, 1107, 1049, 982, 920, 756 cm^{-1}. HRMS *m/z* calcd. for $C_{11}H_{11}ClO_4Na$ [M+Na$^+$]: 265.0244, found: 265.0245.

***syn*-Methyl 2-((3-chlorophenyl)(hydroxy)methyl)oxirane-2-carboxylate 2m.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.44 (1H, s), 7.32 (3H, m), 5.10 (1H, s), 3.73 (3H, s), 3.16 (1H, d, J = 6.0Hz), 2.90 (1H, d, J = 6.0Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 169.6, 140.6, 134.3, 129.6, 128.4, 127.1, 125.3, 71.3, 58.7, 52.8, 49.8 ppm. IR (KBr) δ 3466, 3020, 2964, 1736, 1463, 1264, 1154, 1170, 1083, 962, 918, 877 cm^{-1}.

***syn*-Methyl 2-((2-chlorophenyl)(hydroxy)methyl)oxirane-2-carboxylate 2n.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.54 (1H, m), 7.33 (1H, m), 7.24-7.29 (2H, m), 6.04 (1H, s), 3.82 (3H, s), 3.06 (1H, d, J = 6.0Hz), 2.35 (1H, d, J = 6.0Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 169.9, 135.0, 132.9, 129.5, 127.9, 126.9, 67.9, 58.6, 52.9, 50.5 ppm. IR (KBr) δ 3741, 3019, 2938, 1734, 1472, 1390, 1297, 1195, 1064, 1028, 1028, 758, 741 cm^{-1}.

***syn*-Methyl 2-((4-bromophenyl)(hydroxy)methyl)oxirane-2-carboxylate 2o.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.48 (2H, d, J = 8.0Hz), 7.32 (2H, d, J = 8.0Hz), 5.29 (1H, s), 3.73 (3H, s), 3.14 (1H, d, J = 6.0Hz), 2.88 (1H, d, J =

6.0Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 169.6, 137.5, 131.5, 129.0, 122.2, 71.2, 58.7, 52.7, 48.9 ppm. IR (KBr) δ 3711, 3077, 2957, 2360, 1923, 1592, 1728, 1460, 1333, 1286, 1196, 1127, 1049, 935, 755 cm^{-1}. HRMS *m/z* calcd. for $C_{11}H_{11}BrO_4Na$ [M+Na^+]: 308.9738, found: 308.9735.

***syn*-Methyl 2-((2-nitrophenyl)(hydroxy)methyl)oxirane-2-carboxylate 2p.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.96 (1H, dd, J = 8.2, 1.3Hz), 7.79 (1H, dd, J = 7.9, 1.3Hz), 7.65 (1H, td, J = 7.7, 1.3Hz), 7.48 (1H, td, J = 8.5, 1.4Hz), 6.17 (1H, s), 3.82 (3H, s), 3.13 (1H, d, J = 6.0Hz), 2.37 (1H, d, J = 6.0Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 169.6, 148.3, 133.3, 129.8, 129.1, 124.6, 66.8, 58.1, 53.1, 51.0 ppm. IR (KBr) δ 3648, 3093, 2957, 1725, 1440, 1357, 1267, 1200, 1156, 1053, 947, 747 cm^{-1}.

***syn*-Methyl 2-((3-nitrophenyl)(hydroxy)methyl)oxirane-2-carboxylate 2q.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 8.33 (1H, m), 8.17 (1H, ddd, J = 8.2, 2.3, 1.2Hz), 7.81 (1H, m), 7.52 (1H, t, J = 7.92 Hz), 5.19 (1H, s), 3.74 (3H, s), 3.22 (1H, d, J = 6.0Hz), 2.95 (1H, d, J = 6.0Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 169.4, 148.2, 133.3, 129.2, 123.2, 122.1, 71.0, 65.7, 52.8, 49.7 ppm. IR (KBr) δ 3712, 3092, 3006, 2957, 2876, 1735, 1441, 1353, 1289, 1163, 1096, 976, 935, 866, 758 cm^{-1}.

***syn*-Methyl 2-((4-nitrophenyl)(hydroxy)methyl)oxirane-2-carboxylate 2r.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 8.22 (2H, d, J = 8.0Hz), 7.65 (2H, d, J = 8.0Hz), 5.13 (1H, s), 3.73 (3H, s), 3.48 (1H, d, J = 6.0Hz), 2.94 (1H, d, J = 6.0Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 169.5, 146.0, 128.1, 127.8, 123.4, 71.4, 58.4, 53.0, 49.9 ppm. IR (KBr) δ 3902, 3087, 2958, 2342, 1925, 1715, 1517, 1442, 1221, 1096, 1053, 946, 777 cm^{-1}. HRMS *m/z* calcd. for $C_{11}H_{11}NO_6Na$ [M+Na^+]: 276.0484, found: 276.0482.

***syn*-Methyl 2-(furan-2-yl(hydroxy)methyl)oxirane-2-carboxylate 2s.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.38 (1H, s), 7.26 (1H, s), 6.39 (1H, m), 6.33 (1H, m), 5.29 (1H, s), 3.75 (3H, s), 3.23 (1H, d, J = 6.0Hz), 3.05 (1H, d, J = 6.0Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 169.3, 125.6, 142.5, 110.4, 107.7, 64.5, 52.6, 49.0 ppm. IR (KBr) δ 3932, 3153, 3004, 2957, 1734, 1633, 1359, 1231, 1048, 975, 753 cm^{-1}.

General experimental procedure for the preparation of cyclic carbonates:

An ice-bath cold suspension of sodium hydride (60% in mineral oil) (1.12 mmol) in THF (1 mL) was treated with

thiophenol (2.25 mmol). The mixture was stirred at room temperature for 15 min and then a solution of the epoxyester 2 (0.75 mmol) in THF (1 mL) was added drop wise and the mixture was stirred at room temperature for 1.5 h. Then was treated with pyridine (0.22 mmol) and triphosgene (0.48 mmol). The mixture was refluxed for 15 h. Then brine was added and extracted with Et_2O (3 x 20 mL), the organic layers were washed (brine), dried (Na_2SO_4), and concentrated. The crude oil was purified through chromatography (silica-gel, hexanes/EtOAc (8:2) and (7:3)).

***syn*-Methyl 5-isobutyl-2-oxo-4-((phenylthio)methyl)-1,3-dioxolane-4-carboxylate 4.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.46 (2H, m), 7.25-7.33 (3H, m), 4.73 (1H, m), 3.81 (3H, s), 3.58 (1H, d, J = 15.0Hz), 3.47 (1H, d, J = 15.0Hz), 1.77 (1H, m), 1.44 (1H, m), 1.35 (1H, m), 0.92 (3H, d, J = 6.5Hz), 0.84 (3H, d, J = 6.5Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 167.7, 152.7, 134.7, 131.3, 129.3, 127.7, 86.6, 80.4, 53.2, 39.6, 38.6, 25.1, 23.0, 21.2 ppm. IR (KBr) δ 3059, 2959, 1811, 1743, 1626, 1540, 1470, 1387, 1306, 1200, 1116, 1025, 968, 746 cm^{-1}. HRMS *m/z* calcd. for $C_{16}H_{20}O_5SNa$ [M+Na$^+$]: 347.0929, found: 347.0929.

***anti*-Methyl 5-isobutyl-2-oxo-4-((phenylthio)methyl)-1,3-dioxolane-4-carboxylate 5.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.46 (2H, m), 7.25-7.33 (3H, m), 4.76 (1H, m), 3.70 (3H, s), 3.42 (2H, s), 1.71 (1H, m), 1.49 (1H, m), 1.47 (1H, m), 0.98 (3H, d, J = 6.5Hz), 0.95 (3H, d, J = 6.5Hz). ^{13}C NMR (125 MHz, $CDCl_3$) δ 168.6, 152.2, 134.4, 131.9, 129.2, 127.8, 85.6, 80.4, 53.4, 37.9, 37.5, 24.9, 23.2, 21.2 ppm. IR (KBr) δ 3059, 2959, 1806, 1749, 1582, 1439, 1360, 1257, 1132, 1048, 963, 744 cm^{-1}.

***syn*-Methyl 5-cyclohexyl-2-oxo-4-((phenylthio)methyl)-1,3-dioxolane-4-carboxylate 6.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.39 (2H, m), 7.25-7.17 (3H, m), 4.37 (1H, m), 3.73 (3H, s), 3.57 (1H, d, J = 15.0Hz), 3.35 (1H, d, J = 15.0Hz), 1.80 (1H, m), 1.40-1.77 (5H, m), 1.24-0.79 (5H, m). ^{13}C NMR (125 MHz, $CDCl_3$) δ 168.9, 152.4, 134.8, 131.9, 129.2, 127.8, 86.0, 85.7, 53.5, 37.7, 37.3, 29.5, 28.1, 25.7, 25.4, 25.1 ppm. IR (KBr) δ 3060, 2929, 2857, 1741, 1582, 1402, 1195, 1024, 927, 845, 713, 629 cm^{-1}. HRMS *m/z* calcd. for $C_{18}H_{22}O_5SNa$ [M+Na$^+$]: 373.1086, found: 373.1089.

***anti*-Methyl 5-cyclohexyl-2-oxo-4-((phenylthio)methyl)-1,3-dioxolane-4-carboxylate 7.** ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.47 (2H, m), 7.24-7.33 (3H, m), 4.43 (1H, m), 3.76 (3H, s), 3.56 (1H, d, J = 15.0Hz), 3.48 (1H, d, J =

15.0Hz), 1.77 (1H, m), 1.68-1.76 (5H, m), 1.10-1.25 (5H, m). ^{13}C NMR (125 MHz, $CDCl_3$) δ 167.9, 152.6, 134.7, 131.7, 129.2, 127.7, 86.6, 85.8, 53.3, 40.8, 38.6, 28.6, 28.5, 25.7, 25.2, 25.0 ppm. IR (KBr) δ 2934, 2854, 1747, 1584, 1584, 1440, 1178, 1052, 930, 634 cm^{-1}.

Acknowledgements

This work was financed by Bancaixa-UJI foundation (P1 1B2011-59 and P1 1B2011-28). The authors also are grateful to the Serveis Centrals d'Instrumentació Científica (SCIC) of the Universitat Jaume I for providing us with mass spectrometry and NMR.

References and Footnotes

1- Chong, J. M.; Sharpless, K. B. *Tetrahedron Lett*. **1985**, *26*, 4683-4686.

2- Meth-Cohn, O.; Moore, C.; Taljaard, H. C. *J. Chem. Soc., Perkin Trans. 1* **1988**, 2663-2674.

3- Saito, S.; Takahashi, N.; Ishikawa, T.; Moriwake, T. *Tetrahedron Lett*. **1991**, *32*, 667-670.

4- Lanier, M.; Pastor, R. *Tetrahedron Lett*. **1995**, *36*, 2491-2492.

5- Righi, G.; Rumboldt, G.; Bonini, C. *J. Org. Chem*. **1996**, *61*, 3557-3560.

6- Concellón, J. M.; Bardales, E. *Org. Lett*. **2002**, *4*, 189-191.

7- Concellón, J. M.; Bardales, E.; Llavona, R. *J. Org. Chem*. **2003**, *68*, 1585-1588 and refs cited therein.

8- Rodríguez, S.; Izquierdo, F.; López, I.; González, F. V. *Tetrahedron* **2006**, *62*, 11112-11123.

9- López, I.; Izquierdo, J.; Rodríguez, S.; González, F. V. *J. Org. Chem*. **2007**, *72*, 6614-6617.

10- Bailey, M.; Markó, I. E.; Ollis, W. D.; Rasmussen, P. R. *Tetrahedron Lett*. **1990**, *31*, 4509-4512.

11- Bailey, M.; Staton, I.; Ashton, P. R.; Markó, I. E.; Ollis, W. D. *Tetrahedron: Asymm*. **1991**, *2*, 495-509.

12- Svenda, M.; Myers, A. G. *Org. Lett*. **2009**, *11*, 2437-2440.

13- Yu, C.; Liu, B.; Hu, L. *J. Org. Chem*. **2001**, *66*, 5413-5418.

14- García-Ruano, J. L.; Fajardo, C.; Fraile, A.; Martí, M. R. *J. Org. Chem*. **2005**, *70*, 4300-4306.

15- Adam, W.; Braun, M.; Griesbek, A.; Lucchini, V.; Staab, E.; Will, B. *J. Am. Chem. Soc.* **1989**, *111*, 203-212.

16- Lee, K.; Loh, T. *Chem. Commun.* **2006**, *40*, 4209-4211.

17- Brzezinski, L. J.; Rafel, S.; Leahy, J. W. *Tetrahedron* **1997**, *53*, 16423-16434.

18- Mi, X.; Luo, S.; Cheng, J. *J. Org. Chem.* **2005**, *70*, 2338-2341.

19- Aggarwal, V. A.; Emme, I.; Fulford, S. Y. *J. Org. Chem.* **2003**, *68*, 692-700.

20- Guo, Y.; Shao, G.; Li, L.; Wu, W.; Li, R.; Li, J.; Song, J.; Qiu, L.; Prashad, M.; Kwong, F. Y. *Adv. Synth. Cat.* **2010**, *352*, 1539-1553.

Supporting Information

Study of the Stereoselectivity of the Nucleophilic Epoxidation of 3-Hydroxy-2-methylene Esters

Antonio Latorre, José A. Sáez, Santiago Rodríguez, Florenci V. González*

Departament de Química Inorgànica i Orgànica, Universitat Jaume I, 12080 Castelló, Spain

Contents


1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
Me
OH
O
OMe
1a
1.00
0.37
0.95
0.33
0.33
0.33
f1 (ppm)


22.12
51.83
67.18
76.93
123.98
143.58
167.06
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)
OH
O
Me
OMe
1a


OH
O
Et
OMe
1b
3.29
2.29
1.13
2.84
0.98
1.02
1.00
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H


9.86
29.02
51.47
71.92
77.38
124.70
142.26
166.94
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
OH
O
Et
OMe
1b
f1 (ppm)


OH
O
n-Pr
OMe
1c
3.46
2.54
2.19
1.56
3.00
1.04
1.11
1.10
f1 (ppm)
1 Solvent cdcl3
2 Temperature 26.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H


13.95
19.02
38.54
51.98
71.29
76.98
124.71
142.45
167.04
1 Solvent cdcl3
2 Temperature 26.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)
OH
O
n-Pr
OMe
1c


OH
O
i-Bu
OMe
1d
f1 (ppm)


21.78
23.30
24.82
45.46
51.91
69.88
77.10
124.63
142.82
167.03
1 Solvent cdcl3
2 Temperature 26.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)
i-Bu
OMe
1d


OH
O
Chx
OMe
1e
1.00
1.17
0.21
0.55
0.19
0.20
0.21
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H


OH
O
Chx
OMe
1e
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C


OH
O
Ph
OMe
1f
1 Solvent cdcl3
2 Temperature 26.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
2.43
1.58
2.55
3.00
1.09
1.09
1.18
5.83
f1 (ppm)


OH
O
Ph
OMe
1f
f1 (ppm)
32.02
37.97
51.82
70.13
124.95
125.86
128.38
128.49
141.82
166.98
1 Solvent cdcl3
2 Temperature 26.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C


OH
O
Ph
OMe
1g
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
0.18
0.53
0.19
0.20
0.37
0.21
1.00
f1 (ppm)


OH
O
Ph
OMe
1g
51.99
72.05
76.76
77.01
77.26
125.80
126.58
127.80
128.53
129.23
131.45
136.46
141.29
166.73
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)


OH
O
Ph
OMe
1h
3.00
0.54
0.84
0.86
0.85
4.04
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H


OH
O
Ph
OMe
1h
51.77
72.65
77.32
125.58
126.75
127.71
128.32
141.56
142.33
166.66
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)


OH
O
OMe
Me
1i
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 300.12
4 Nucleus 1H
f1 (ppm)
0.76
0.21
0.75
0.23
0.26
0.26
1.00


OH
O
OMe
Me
1i
f1 (ppm)
21.09
51.86
73.08
76.58
77.00
77.43
125.76
126.49
129.10
137.50
138.36
142.09
166.75
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 75.47
4 Nucleus 13C


OH
O
OMe
MeO
1j
0.38
1.44
1.40
0.45
0.50
0.48
0.89
1.00
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 300.12
4 Nucleus 1H


OH
O
OMe
MeO
1j
51.86
55.22
72.74
76.58
77.00
77.43
113.82
125.52
127.86
133.46
142.20
159.22
166.75
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 75.47
4 Nucleus 13C
f1 (ppm)


OH
O
OMe
F
1k
0.87
3.00
0.97
1.01
1.05
1.94
1.95
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H


OH
O
OMe
F
1k
51.94
72.56
76.74
77.00
77.25
115.15
115.32
125.08
126.00
128.26
128.33
137.06
141.91
166.64
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)


OH
O
OMe
Cl
1l
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 300.12
4 Nucleus 1H
0.21
0.84
0.26
0.28
0.28
1.00
f1 (ppm)


OH
O
OMe
Cl
1l
52.00
72.74
76.55
76.98
77.40
126.33
127.92
128.56
133.60
139.76
141.62
166.59
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 75.47
4 Nucleus 13C
f1 (ppm)


OH
O
OMe
1m
Cl
1 Solvent cdcl3
2 Temperature 29.0
3 Spectrometer Frequency 300.12
4 Nucleus 1H
0.95
3.61
1.14
1.22
1.18
3.70
1.00
f1 (ppm)


OH
O
OMe
1m
Cl
f1 (ppm)


OH
O
OMe
Cl
1n
f1 (ppm)


OH
O
OMe
Cl
1n
52.02
68.94
126.79
126.95
128.14
128.93
129.39
132.80
138.49
140.88
166.86
1 Solvent cdcl3
2 Temperature 29.0
3 Spectrometer Frequency 75.47
4 Nucleus 13C
f1 (ppm)


OH
O
OMe
Br
1o
1.55
0.49
0.53
0.53
0.53
1.00
1.00
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H


OH
O
OMe
Br
1o
51.95
51.94
71.93
121.61
125.86
128.55
131.40
140.62
141.88
166.43
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)


OH
O
OMe
NO2
1p
f1 (ppm)
3.00
0.99
0.95
0.99
0.94
0.94
0.94
0.92


OH
O
OMe
NO2
1p
f1 (ppm)
1 Solvent d2o
2 Temperature 26.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C


OH
O
OMe
1q
NO2
f1 (ppm)


OH
O
OMe
NO2
Iq
52.26
72.38
77.14
121.66
122.80
126.92
129.46
132.77
141.04
143.70
148.30
166.24
f1 (ppm)


OH
O
OMe
O_2N
1r
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
1.00
3.20
1.09
1.13
1.22
2.13
2.13
f1 (ppm)


OH
O
OMe
O_2N
1r
52.17
72.70
77.25
77.00
76.75
123.58
127.31
127.18
140.99
148.57
166.35
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)


OH
O
OMe
O
1s
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
f1 (ppm)
1.00
3.33
1.03
1.18
1.00
0.94
1.11
1.01


51.99
52.01
67.24
76.77
77.02
77.28
107.13
110.37
126.71
139.47
142.31
154.14
166.42
OMe
Is
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)


OH
Me
OMe
2a/3a
f1 (ppm)


18.21
18.61
49.29
49.31
52.47
52.49
58.95
59.60
64.91
65.09
76.89
77.14
77.40
170.02
169.86
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)
OH
O
Me
OMe
O
2a/3a


OH
O
Et
OMe
O
2a/3b
3.00
1.60
1.22
1.42
0.93
0.91
3.81
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H




OH
O
Ph
nMe
O
2c
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
3.02
4.65
1.01
1.00
2.70
1.00
f1 (ppm)


13.75
18.69
34.95
49.56
52.49
58.29
69.33
76.85
77.10
77.35
169.96
f1 (ppm)
OH
O
Et
OMe
O
2a


OH
O
Et
OMe
O
3a
3.38
4.70
1.43
1.10
1.08
3.15
1.00
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H


13.74
18.85
35.12
49.29
52.48
52.47
59.38
68.99
76.82
77.07
77.33
170.04
f1 (ppm)
Et
OMe
3c


OH
O
OMe
O
2d
6.00
2.09
1.30
0.91
0.95
2.66
0.99
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H


21.39
23.51
24.41
41.81
49.64
52.44
52.45
58.45
67.92
76.81
77.07
77.32
170.01
OH
O
OMe
O
2d
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)


OH
O
OMe
O
3d
6.00
1.02
1.04
1.11
1.24
0.93
0.99
2.69
0.92
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H


21.30
23.54
24.48
41.96
49.33
52.50
59.57
67.50
76.77
77.03
77.28
170.06
f1 (ppm)


OH
O
OMe
O
2e
6.31
6.77
1.10
1.10
1.07
3.00
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H


OH
O
OMe
O
2e
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C


OH
O
OMe
O
3e
6.00
1.02
1.04
1.11
1.24
0.93
0.99
2.69
0.92
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H


21.30
23.54
24.48
41.96
49.33
52.50
59.57
67.50
76.77
77.03
77.28
170.06
f1 (ppm)


OH
O
Ph
OMe
O
2l
f1 (ppm)


OH
O
Ph
OMe
O
2f
31.67
34.77
49.34
52.62
58.29
68.93
126.11
128.44
141.45
170.03
f1 (ppm)


OH
O
Ph
OMe
O
3l
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
3.24
1.17
1.12
2.09
3.00
1.04
5.20
f1 (ppm)


31.84
34.51
49.29
52.58
59.08
68.87
76.76
77.01
77.27
126.00
128.41
128.42
141.29
169.99
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)


OH
O
Ph
OMe
O
2g/3g
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H


49.17
49.87
52.68
52.72
58.51
59.00
70.05
70.70
76.70
77.13
77.55
125.56
125.86
126.68
128.04
128.06
128.57
133.13
133.53
136.17
169.84
f1 (ppm)


Ph
OMe
2h/3h
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
f1 (ppm)


OH
O
Ph
OMe
O
2h/3h
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 75.47
4 Nucleus 13C


OH
O
OMe
O
Me
2i/3i
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
f1 (ppm)


OH
O
OMe
O
Me
2i/3i
21.08
48.86
49.55
52.42
52.56
59.13
70.03
71.41
76.84
77.27
77.69
127.00
127.17
128.92
129.05
135.47
137.88
169.79
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 75.47
4 Nucleus 13C
f1 (ppm)


OH
O
OMe
O
MeO
2j/3j
f1 (ppm)


OH
O
OMe
O
MeO
2j/3j
f1 (ppm)
48.85
49.53
52.60
55.18
59.09
71.15
113.69
113.82
128.32
128.49
130.38
159.52
169.77
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C


OH
O
OMe
O
F
2k/3k
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
f1 (ppm)


OH
O
OMe
O
F
2k/3k
f1 (ppm)


OH
O
OMe
O
Cl
2l/3l
f1 (ppm)


OH
O
OMe
O
Cl
2l/3l
49.74
52.76
58.75
71.21
76.88
77.13
77.39
125.21
127.17
128.41
129.57
134.21
140.60
169.59
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)


OH
O
OMe
O
Cl
2m/3m
f1 (ppm)


OH
O
OMe
O
2m/3m
Cl
f1 (ppm)
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C


OH
O
OMe
O
Cl
2n/3n
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
1.10
0.84
1.23
2.99
0.96
3.50
1.00
f1 (ppm)


OH
O
OMe
O
Cl
2n/3n
f1 (ppm)


OH
O
OMe
O
Br
2o/3o
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
0.51
0.87
1.26
0.17
0.43
0.07
1.05
1.00
f1 (ppm)


OH
O
OMe
O
Br
2o/3o
49.56
52.59
58.73
71.07
122.17
128.81
131.52
137.34
169.73
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)


OH
O
OMe
O
NO2
2p/3p
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
f1 (ppm)


OH
O
OMe
O
NO2
2p/3p
48.29
50.87
53.21
58.83
58.02
67.02
123.93
124.72
128.32
129.04
129.84
133.43
169.67
170.46
f1 (ppm)


OH
O
OMe
O
NO2
2q/3q
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
f1 (ppm)


OH
O
OMe
O
NO2
2q/3q
49.17
49.83
52.96
58.50
69.62
70.94
77.08
122.27
123.29
129.29
133.12
140.73
148.06
169.49
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)


OH
O
OMe
O
O2N
2r/3r
f1 (ppm)


OH
O
OMe
O
O2N
2r/3r
f1 (ppm)


OH
O
OMe
O
O
2s/3s
1.00
1.00
2.92
0.87
1.81
0.91
f1 (ppm)


OH
O
OMe
O
2s/3s
48.99
52.61
58.37
64.50
107.70
110.37
142.46
152.61
169.25
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)


CO2Me
PhS
4
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
f1 (ppm)


21.20
23.03
25.08
38.62
39.64
53.21
76.82
77.07
77.32
80.38
86.61
127.68
129.29
131.34
134.68
152.71
167.74
CO2Me
PhS
4
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)



4




CO2Me
PhS
5
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
f1 (ppm)


21.13
23.17
24.89
37.49
37.82
53.30
76.79
77.05
77.31
80.29
85.54
127.79
129.13
131.89
134.33
152.17
168.53
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)
CO2Me
PhS
5



5



5


1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
f1 (ppm)
2.46
2.89
1.02
1.33
0.51
1.41
1.00
CO2Me
PhS
6


f1 (ppm)
25.08
25.39
25.71
28.10
29.46
37.30
37.70
53.50
76.84
77.09
77.35
85.67
85.99
127.81
129.20
131.93
134.78
152.42
168.88
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C




CO2Me
PIII3
7
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 499.82
4 Nucleus 1H
f1 (ppm)
3.32
3.69
0.68
0.58
1.50
0.58
1.62
1.00


25.02
25.22
25.67
28.53
28.61
38.59
40.84
53.25
76.84
77.09
77.34
85.55
85.77
127.73
129.24
131.71
134.66
152.61
167.93
CO2Me
PhS
7
1 Solvent cdcl3
2 Temperature 30.0
3 Spectrometer Frequency 125.69
4 Nucleus 13C
f1 (ppm)



7